Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Cell Death Differ. 2010 Jan;17(1):4-13. doi: 10.1038/cdd.2009.82.

Therapeutic strategies within the ubiquitin proteasome system.

Author information

  • 1Department of Cell Regulation, Genentech Inc., South San Francisco, CA 94080, USA. eldridge.adam@gene.com


The ubiquitin-dependent proteolysis system (UPS) is the main driver of regulated protein degradation in all eukaryotic cells, and it is becoming increasingly clear that defects within this pathway drive a large number of human pathologies. Recent success in the use of proteasome inhibitors in the treatment of hematological malignancies validates the UPS as a viable therapeutic pathway, and substantial effort is now focused on the development of both second-generation proteasome inhibitors as well as novel strategies for the inhibition of upstream UPS enzymes. In this review we discuss the potential 'druggability' of key nodes within the UPS and summarize recent advances within the field.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk